公开(公告)号：US20250034576A1

公开(公告)日：2025-01-30

申请号：US18743170

申请日：2024-06-14

Applicant: Hoffmann-La Roche Inc.

Inventor： Philipp Friedrich BERNINGER ,  Konrad BLEICHER ,  Erik FUNDER ,  Helle JACOBSEN ,  Dennis Jul HANSEN ,  Michael KELLER ,  Inna Appeldorff LARSEN ,  Meiling LI ,  Disa Elisabet TEHLER ,  Lotte WINTHER ,  Jesper WORM ,  Lena WYSS ,  Tiago Francisco SANTOS FERREIRA

IPC: C12N15/113

Abstract: The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.